Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) said Monday it entered a global licensing and collaboration agreement with OncoGenex Pharmaceuticals Inc. (NASDAQ: OXGI), according to Associated Press.
Free Hot Penny Stocks, an online financial publication, provides investors timely stock market alerts. Free hot penny stocks profiles stock picks that could generate higher returns than average. These penny stocks include stocks with news, chart breakouts or increased volume.
Sign Up Today for our Penny Stock Newsletter
The deal is for OncoGenex’s potential cancer treatment OGX-011 for $60 million, including an equity investment.
The drug candidate is expected to move into late-stage development as a potential prostate and lung cancer treatment in 2010 and 2011, the companies said. The drug is expected to be used an additional therapy to enhance the effectiveness of chemotherapy.
Under the deal, OncoGenex will receive $60 million up front, including a $10 million equity investment valuing its stock at $37.38 per share, which represents a 26 percent premium to its closing price of $29.65 on Friday. OncoGenex will be eligible to receive up to $370 million in milestone and other payments, along with royalties.
OncoGenex, based in Bothell, WA, retains an option to co-promote OGX-011 in the U.S. and Canada.
Sign Up for Free Hot Penny Stocks’ FREE Penny Stock Newsletter.
About Us
Free Hot Penny Stocks is a financial website and independent electronic publication that provides information and free penny stock alerts on selected publicly traded companies. We also track small cap companies and other stocks that may be positioned to break out. These penny stocks might have news, increased volume or chart breakouts. These penny stocks that are alerted could generate greater than average returns. Feel free to visit our penny stock forum to discuss other penny stock picks or penny stocks that you might own.
Free Hot Penny Stocks is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
